# Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

> **NCT01289028** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 125 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT01289028
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2017-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01289028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01289028, "Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01289028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*